Skip to content
IGI grad logo
  • About Us
    • Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Management Team NewGreenArrow
      Board of Directors NewGreenArrow
      Scientific Advisory Board NewGreenArrow
      Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Our Team NewGreenArrow
      Leadership
      Governance Board
      Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
  • News Center
    • News & Media NewGreenArrow
      Publications NewGreenArrow
  • Careers
    • Our Culture NewGreenArrow
      Join Us NewGreenArrow
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us

Uncategorized

  1. Home>
  2. Uncategorized>
  3. Page 3

Team Leader Facilities

  • Post published:January 9, 2024
  • Post category:Uncategorized

Team Leader Facilities Job Type : (12 Months temporary contract) Team Leader Facilities Date : 03 May 2024Location : La Chaux-de-FondsCompany : Ichnos Sciences Inc.RESPONSIBILITIES:Project Management:Coordinate and prioritize a wide…

Continue ReadingTeam Leader Facilities

Quality Control Associate Microbiology

  • Post published:January 9, 2024
  • Post category:Uncategorized

Quality Control Associate Microbiology Job Type : (12 Months temporary contract) Quality Control Associate Microbiology Date : 26 Apr 2024Location : La Chaux-de-FondsCompany : Ichnos Sciences Inc.Quality Control Associate Microbiology(12 months…

Continue ReadingQuality Control Associate Microbiology

Ichnos Sciences Appoints President and CEO Cyril Konto as Executive Director to the Board

  • Post published:January 6, 2024
  • Post category:Uncategorized

DATE: 06 Dec 2023 CATEGORY: UPDATES Ichnos Sciences Appoints President and CEO Cyril Konto as Executive Director to the Board FOR IMMEDIATE RELEASENEW YORK, NYDecember 6, 2023NEW YORK, December 6,…

Continue ReadingIchnos Sciences Appoints President and CEO Cyril Konto as Executive Director to the Board

Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting

  • Post published:January 5, 2024
  • Post category:Uncategorized

DATE: 09 Nov 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting Three poster presentations on three oncology assets, including clinical data on…

Continue ReadingIchnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting
  • Go to the previous page
  • 1
  • 2
  • 3

Recent Updates

  • Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
    July 10, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
    July 9, 2025/
    0 Comments
  • Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
    June 2, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
    May 3, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma​
    December 9, 2024/
    0 Comments

We are open for collaboration

Contact Us
For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

We are open for collaboration

For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

Contact Us
Ichnos Glenmark Innovation creates cutting-edge solutions to treat haematological malignancies and solid tumours to bring new hope for patients and healthcare professionals alike.
  • Terms of Use
  • Privacy Policy
  • Cookies Policy

Get in Touch

© Copyright 2025. All Rights Reserved by IGI.

© Copyright 2025. All Rights Reserved by IGI.

  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Expanded Access Policy
  • Contact Us
  • Linkedin